Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain
NCT ID: NCT00488787
Last Updated: 2008-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2001-03-31
2001-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction
NCT02199678
Ketamine in Post-operative Dental Pain and Recovery
NCT02021240
Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction
NCT00390312
Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction
NCT02356965
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
NCT05508594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Intranasal ketamine low dose
intranasal ketamine
low dose
B
intranasal ketamine medium dose
intranasal ketamine
medium dose
C
intranasal ketamine high dose
intranasal ketamine
high dose
D
placebo
placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intranasal ketamine
low dose
intranasal ketamine
medium dose
intranasal ketamine
high dose
placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Javelin Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Javelin Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyle Christensen, DDS
Role: PRINCIPAL_INVESTIGATOR
Jean Brown Associates
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KET-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.